Low-energy femoral shaft fracture in elderly patient with prolonged use of alendronate

Fraturas diafisárias do fêmur por baixa energia nos pacientes idosos com uso prolongado de alendronato

José Ricardo Negreiros Vicente¹, Daniel Seguel Rebolledo², Marcos Camargo Leonhardt³, Mauricio Bernstein⁴

Study carried at Hospital Israelita Albert Einstein – HIAE, São Paulo (SP), Brasil.

¹ Orthopedic Oncology Group, Faculdade de Medicina, Universidade de São Paulo – USP, São Paulo (SP), Brazil.
² Orthopedic Oncology Group, Faculdade de Medicina do ABC – FMABC, Santo André (SP), Brazil; Master’s degree student at the Department of Orthopedics and Trauma, Faculdade de Medicina, Universidade de São Paulo – USP, São Paulo (SP), Brazil.
³ Hip Group, Department of Orthopedics and Trauma, Faculdade de Medicina, Universidade de São Paulo – USP, São Paulo (SP), Brazil.
⁴ Department of Cardiopneumology, Faculdade de Medicina, Universidade de São Paulo – USP, São Paulo (SP), Brazil; Cardiologist at the Hospital Israelita Albert Einstein – HIAE, São Paulo (SP), Brazil.

Corresponding author: José Ricardo Negreiros Vicente – Rua Afonso de Freitas, 488, apto. 22 - Paraíso – CEP 04006-052 – São Paulo (SP), Brasil – Tel.: 11 3884-0665 – e-mail: jrnegreiro@einstein.br

Received on Jun 30, 2009 – Accepted on Apr 12, 2010

The authors declare there is no conflict of interest.
Fractures in the proximal femur occur in female and male elderly population due to low-energy trauma in osteoporotic bones. In order to prevent these fractures, treatment of osteoporosis has been indicated, particularly using biphosphonates\(^1\).

Alendronate was the first drug approved by the Food and Drug Administration (FDA), in 1995, to treat osteoporosis\(^2\). This drug acts in bone metabolism, inhibiting osteoclasts, inducing their apoptosis\(^3\), raising the bone mineral density and reducing the incidence of osteoporotic fractures\(^4\).

In the past years, some authors described an unusual shaft femoral fracture in elderly women undergoing prolonged treatment of osteoporosis with biphosphonates. These fractures were associated with low-energy trauma or no evidence of any trauma event\(^5,6\).

Femoral structure submitted to physiological stress results in microdamages to bone microstructure. The inhibition of osteoclasts may also lead to severe suppression in bone turnover, leading to accumulation of microdamage\(^7,8\). These processes may make bone brittle and cause unexpected and uncommon femoral fractures.

A recent increase in the incidence of such fractures in patients on alendronate therapy led some authors to conduct a retrospective review of these cases. A characteristic fracture configuration suggestive of an insufficiency stress fracture was identified on plain radiographs. This consists of a cortical thickening in the lateral side of the subtrochanteric region, a transverse or short oblique fracture, and a medial cortical spike (Figure 1).

A retrospective study evaluating 19 patients with this fracture pattern among 70 patients with low-energy shaft fractures was 98% specific to alendronate users\(^6\). Thus, alendronate treatment might be stopped for a while after five years to prevent severe suppression of bone turnover and subsequent stress fractures\(^7\).

REFERENCES
2. FDA- approved Drugs. USA Food and Drug Administration 1995 (date last accessed 1\(^{st}\) February 2007).